tbuckley/cabot-search huggingface dataset:
Interobserver and Intraobserver Agreement on the Treatment of Infantile Hemangiomas
Authors: María Colmenero-Sendra, Javier del Boz-González, Mercè Grau-Pérez, Ricardo Ruiz-Villaverde, Miguel Ángel Descalzo-Gallego, Ignacio García-Doval, Eulalia Baselga Torres
Journal: JAMA Dermatology (2024)

Importance Although clinical practice guidelines exist for the treatment of infantile hemangiomas (IHs), recommendations are heterogeneous, and wide practice variations in IH management have been reported. Objective To analyze the degree of agreement in treatment choices for IH among pediatric dermatologists in North America and Europe and assess whether there are differences across IH risk categories. Design, Setting, and Participants This cross-sectional interrater and intrarater agreement study was conducted through a survey based on the Spanish Academy of Dermatology and Venereology IH prospective cohort. The survey used 50 vignettes of IH cases that were randomly selected from the cohort. It was administered twice in 2023, 1 month apart, to allow for interrater and intrarater agreement assessments. Data were analyzed in January 2024. The study involved pediatric dermatologists from North America (via the Pediatric Dermatology Research Alliance) and Europe (via the European Society of Pediatric Dermatologists). Exposures Participants were asked to choose 1 of 3 treatment options (propranolol, topical timolol, or observation) for each vignette. Main Outcome and Measure The primary outcome was the interrater agreement in treatment choices for IH cases, measured using κ statistics (Gwet AC1 coefficient). Results The global interobserver agreement among 90 pediatric dermatologists was fair (AC1, 0.38; 95% CI, 0.29-0.46). In North America (45 pediatricians), agreement was moderate (AC1, 0.41; 95% CI, 0.33-0.49), while in Europe (45 pediatricians) it was fair (AC1, 0.37; 95% CI, 0.28-0.46). The degree of agreement varied depending on the risk category of IH, with excellent agreement in high-risk IH and only moderate agreement in intermediate-risk and low-risk IHs. Propranolol was predominantly chosen for high-risk IH, while observation was most frequent for low-risk IH (55.9%). The second survey had 61 respondents, with no significant intrarater differences. Conclusions and Relevance The results of this survey study suggest that there is an important variability in the treatment of intermediate-risk and low-risk IH. The study findings support the need for more evidence regarding the role of topical timolol in IH treatment, which may help harmonize treatment approaches and improve consistency in IH management globally.
GOLD COPD Exacerbation History Categories and Disease Outcomes
Authors: Kiki Waeijen-Smit, Daphne E. M. Peerlings, Rudolf A. Jörres, Henrik Watz, Robert Bals, Klaus F. Rabe, Claus F. Vogelmeier, Tim Speicher, Martijn A. Spruit, Sami O. Simons, Sarah Houben-Wilke, Frits M. E. Franssen, Peter Alter
Journal: JAMA Network Open (2024)

Importance Previous exacerbations of chronic obstructive pulmonary disease (ECOPD) are associated with future events. For more than a decade, patients at high risk have been defined as individuals with a history of 2 or more moderate ECOPD, 1 or more severe ECOPD, or both within 12 months, and treatments have been allocated accordingly, but these cutoffs lack validation. Objectives To validate ECOPD history categories by the Global Initiative for Chronic Obstructive Lung Disease (GOLD) and explore alternative cutoffs to estimate moderate and severe ECOPD and all-cause mortality in COPD. Design, Setting, and Participants This cohort study analyzed data from patients with COPD in the German COPD and Systemic Consequences-Comorbidities Network (COSYCONET) study. Patients were recruited from September 2010 to December 2013. Analyses were conducted in September 2023 to August 2024. Main Outcomes and Measures Risk of moderate and severe (ie, with hospitalization) ECOPD and all-cause mortality over a 4.5-year follow-up period were assessed using binomial logistic regressions and area under the receiver operating characteristic curves (AUROCs) with 95% CIs. Results Among 2291 patients with COPD GOLD categories 1 to 4 (mean [SD] age, 65 [8] years; 1396 male [60.9%]), the mean (SD) estimated forced expiratory volume in the first second of expiration was 52.5% (18.6%). ECOPD history categories by GOLD had an AUROC of 0.63 (95% CI, 0.60-0.65) and 0.62 (95% CI, 0.58-0.66) to estimate moderate and severe ECOPD, respectively. A single previous moderate ECOPD within 12 months more accurately estimated future moderate and severe ECOPD (AUROC, 0.66; 95% CI, 0.64-0.69), and in line with GOLD, 1 previous severe ECOPD within 12 months estimated moderate and severe ECOPD (AUROC, 0.63; 95% CI, 0.60-0.67). The 4-year mortality rate was 219 patients (9.6%). Patients with 3 or more previous moderate ECOPD (odds ratio, 2.18; 95% CI, 1.27-3.72) or 1 or more previous severe ECOPD (odds ratio, 1.57; 95% CI, 1.29-1.91) within 12 months were more likely to die compared with patients without prior ECOPD. Conclusions and Relevance This study’s findings suggest a limited estimative performance of ECOPD history categories by GOLD. Novel cutoffs were suggested, categorizing patients as without exacerbations or with high-risk exacerbations based on a history of 1 or more moderate ECOPD, 1 or more severe ECOPD, or both within 12 months.
Pediatric Emergency Care Coordinator Presence and Pediatric Care Quality Measures
Authors: Margaret E. Samuels-Kalow, Rebecca E. Cash, Kenneth A. Michelson, Courtney Benjamin Wolk, Katherine E. Remick, Stephanie S. Loo, Maeve F. Swanton, Elizabeth R. Alpern, Kori S. Zachrison, Carlos A. Camargo
Journal: JAMA Network Open (2024)

Higher pediatric readiness has been associated with improved quality and outcomes of care for children. Pediatric emergency care coordinators (PECCs) are a component of pediatric readiness, but the specific association between PECCs and quality-of-care measures is undefined.
Unmasking Racial and Ethnic Disparities in Child Physical Abuse Identification
Authors: Allison M. Jackson
Journal: JAMA Network Open (2024)

Fereshteh Salimi-Jazi, MD; Norah E. Liang, MD; Zhuoyi Huang, MS; Lakshika Tennakoon, MD, MPhil; Talha Rafeeqi, MBBS; Amber Trickey, PhD; Stephanie D. Chao, MD
Incidence of and Risk Factors for Cutaneous Malignant Neoplasms After Blood or Marrow Transplant
Authors: Kristy K. Broman, Qingrui Meng, Anna Holmqvist, Nora Balas, Joshua Richman, Wendy Landier, Lindsey Hageman, Elizabeth Ross, Alysia Bosworth, Hok Sreng Te, Britany Hollenquest, F. Lennie Wong, Ravi Bhatia, Stephen J. Forman, Saro H. Armenian, Daniel J. Weisdorf, Smita Bhatia
Journal: JAMA Dermatology (2024)

Cutaneous malignant neoplasms are the most common subsequent neoplasm after blood or marrow transplant (BMT), but a full assessment among survivors is lacking.
Self-Guided vs Clinician-Guided Online Cognitive Behavioral Therapy for Atopic Dermatitis
Authors: Dorian Kern, Brjánn Ljótsson, Louise Lönndahl, Erik Hedman-Lagerlöf, Olof Molander, Björn Liliequist, Maria Bradley, Nils Lindefors, Martin Kraepelien
Journal: JAMA Dermatology (2024)

Importance Clinician-guided online self-help based on cognitive behavioral therapy (CBT) has been shown to be effective at decreasing symptom severity for people with atopic dermatitis (AD). A brief online self-guided CBT intervention could be more cost-effective and allow for easy implementation and broader outreach compared with more comprehensive clinician-guided interventions. Objective To investigate whether a brief online self-guided CBT intervention is noninferior to a comprehensive online clinician-guided CBT treatment. Design, Setting, and Participants This single-blind randomized clinical noninferiority trial was conducted at Karolinska Institutet, Stockholm, Sweden. Adult individuals with AD were enrolled from November 2022 to April 2023. The last postintervention data were collected in December 2023. Interventions Participants randomized to the self-guided group had access to a self-guided online CBT intervention for 12 weeks without clinician support. Participants randomized to the clinician-guided group received online CBT for 12 weeks. Main Outcomes and Measures The primary outcome was change in score from baseline to postintervention to 12-week follow-up on the self-reported Patient-Oriented Eczema Measure (POEM). The predefined noninferiority margin was 3 points on POEM. Results Of 168 randomized participants, 142 (84.5%) were female, and the mean (SD) age was 39 (10.5) years. A total of 86 participants were randomized to the self-guided group and 82 were randomized to the clinician-guided group. A total of 151 (90.0%) completed the main outcome postintervention assessment. Postintervention, the clinician-guided group had improved 4.20 points (95% CI, 1.94-6.05) on POEM and the self-guided group improved 4.60 points (95% CI, 2.57-6.64), corresponding to an estimated mean difference in change of 0.36 points (1-sided 97.5% CI, −∞ to 1.75), which was below the noninferiority margin of 3 points. No serious adverse events were reported. In the clinician-guided group, clinicians spent a mean (SD) of 36.0 (33.3) minutes (95% CI, 29.2-41.7) on treatment guidance and 14.0 (6.0) minutes (95% CI, 12.9-15.6) on assessments compared to 15.8 (6.4) minutes on assessments in the self-guided group. Conclusions and Relevance In this randomized clinical noninferiority trial, a brief self-guided CBT intervention was noninferior to clinician-guided CBT. Given the limited clinical resources required to deliver self-guided CBT, this treatment might be a promising means to disseminate evidence-based psychological treatment for patients with AD. Trial Registration ClinicalTrials.gov Identifier: NCT05517850
Potassium Nitrate in Heart Failure With Preserved Ejection Fraction
Authors: Payman Zamani, Sanjiv J. Shah, Jordana B. Cohen, Manyun Zhao, Wei Yang, Jessica L. Afable, Maria Caturla, Hannah Maynard, Bianca Pourmussa, Cassandra Demastus, Ipsita Mohanty, Michelle Menon Miyake, Srinath Adusumalli, Kenneth B. Margulies, Stuart B. Prenner, David C. Poole, Neil Wilson, Ravinder Reddy, Raymond R. Townsend, Harry Ischiropoulos, Thomas P. Cappola, Julio A. Chirinos
Journal: JAMA Cardiology (2024)

Nitric oxide deficiency may contribute to exercise intolerance in patients with heart failure with preserved ejection fraction (HFpEF). Prior pilot studies have shown improvements in exercise tolerance with single-dose and short-term inorganic nitrate administration.
A New Look at a Tenacious Problem—Resident Work-Hour Violations
Authors: Luise I. Pernar
Journal: JAMA Surgery (2024)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA Surgery HomeNew OnlineCurrent IssueFor Authors Podcast JAMA+ AI Journals JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2024 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA Surgery journal
Racial and Ethnic Disparities in Child Abuse Identification and Inpatient Treatment
Authors: Fereshteh Salimi-Jazi, Norah E. Liang, Zhuoyi Huang, Lakshika Tennakoon, Talha Rafeeqi, Amber Trickey, Stephanie D. Chao
Journal: JAMA Network Open (2024)

Child abuse is a leading cause of morbidity in early childhood. Accurate detection remains challenging.
Test Results Are Inconclusive
Authors: Jenna Rindo
Journal: JAMA (2024)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors JAMA+ AI Journals JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2024 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Does Vaccination Really Mitigate Psychiatric Implications of COVID-19?—Reply
Authors: Venexia M. Walker, Praveetha Patalay, Jonathan A. C. Sterne
Journal: JAMA Psychiatry (2024)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA Psychiatry HomeNew OnlineCurrent IssueFor Authors Podcast JAMA+ AI Journals JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2024 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA Psychiatry journal
Poetry, Like Medicine, Can Be Strange
Authors: Rafael Campo
Journal: JAMA (2024)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors JAMA+ AI Journals JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2024 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Characterizing Residents’ Clinical Experiences—A Step Toward Precision Education
Authors: Jesse Burk-Rafel, Carolyn B. Drake, Daniel J. Sartori
Journal: JAMA Network Open (2024)

Andrew C. L. Lam, MD; Brandon Tang, MD, MMSc; Chang Liu, BSc; Marwa F. Ismail, MD, MSc; Surain B. Roberts, PhD; Matthew Wankiewicz, BSc; Anushka Lalwani, MD; Daniel Schumacher, MD, PhD, MEd; Benjamin Kinnear, MD, MEd; Amol A. Verma, MD, MPhil; Fahad Razak, MD, MSc; Brian M. Wong, MD; Shiphra Ginsburg, MD, PhD
Supporting Pediatric Emergency Care Coordinators in All US EDs—A Moral Imperative
Authors: Marc A. Auerbach, Elizabeth Sanseau
Journal: JAMA Network Open (2024)

Margaret E. Samuels-Kalow, MD, MPhil, MSHP; Rebecca E. Cash, PhD; Kenneth A. Michelson, MD, MPH; Courtney Benjamin Wolk, PhD; Katherine E. Remick, MD; Stephanie S. Loo, PhD; Maeve F. Swanton, BS; Elizabeth R. Alpern, MD, MSCE; Kori S. Zachrison, MD, MSc; Carlos A. Camargo Jr, MD, DrPH
Preventing Declines in Cardiovascular Health From Childhood
Authors: Natalie A. Cameron, Norrina B. Allen
Journal: JAMA Cardiology (2024)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA Cardiology HomeNew OnlineCurrent IssueFor Authors Podcast JAMA+ AI Journals JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2024 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA Cardiology journal
Necrotic Plaque in a Patient With Malignant Hematologic Disease
Authors: Marika Matsuya, Motoshi Kinouchi, Yuzufumi Sekiguchi
Journal: JAMA Dermatology (2024)

A man in his 70s with myelodysplastic syndrome presented with a painful violaceous eruption on his left lower leg accompanied by low-grade fever and fatigue for 1 week. What is your diagnosis?
Chest Pain in a Middle-Aged Man
Authors: Qinghua Chang, Zhaolong Xu, Renguang Liu
Journal: JAMA Cardiology (2024)

A man in his mid-50s presented with chest pain lasting 30 minutes. The initial electrocardiogram showed type A preexcitation syndrome, with obvious ST-segment depression in leads V3 through V5 and positive delta wave. What would you do next?
Thresholds for Exacerbation Risk in COPD—Threading the Needleoi
Authors: Surya P. Bhatt
Journal: JAMA Network Open (2024)

Kiki Waeijen-Smit, MSc; Daphne E. M. Peerlings, MSc; Rudolf A. Jörres, MD, PhD; Henrik Watz, PhD; Robert Bals, PhD; Klaus F. Rabe, PhD; Claus F. Vogelmeier, PhD; Tim Speicher, MSc; Martijn A. Spruit, PhD; Sami O. Simons, MD, PhD; Sarah Houben-Wilke, PhD; Frits M. E. Franssen, MD, PhD; Peter Alter, MD, PhD
Does Vaccination Really Mitigate Psychiatric Implications of COVID-19?
Authors: Yaakov Ophir, Yaffa Shir-Raz
Journal: JAMA Psychiatry (2024)

To the Editor The claim in the study by Walker et al that vaccination may mitigate psychiatric implications of COVID-19 infection1 comprises 2 subclaims: (1) vaccination protects against COVID-19 infections/severe illness, and (2) COVID-19 infections/severe illness have psychiatric outcomes.
Trends in Endovascular Aortic Repair Volume and Surveillance in the Era of the MISSION Act
Authors: Aravind S. Ponukumati, Laura Newton, Jesse A. Columbo, David Soybel, Louise Davies, Emily Spangler, Philip Goodney
Journal: JAMA Surgery (2024)

This cohort study examines US veterans undergoing endovascular aortic repairs between 2000 and 2023 in the context of the 2018 Maintaining Internal Systems and Strengthening Integrated Outside Networks (MISSION) Act, which established a community care program to deliver health care to veterans outside Veterans Affairs facilities.
Brexpiprazole and Sertraline Combination Treatment in Posttraumatic Stress Disorder
Authors: Lori L. Davis, Saloni Behl, Daniel Lee, Hui Zeng, Taisa Skubiak, Shelley Weaver, Nanco Hefting, Klaus Groes Larsen, Mary Hobart
Journal: JAMA Psychiatry (2024)

New pharmacotherapy options are needed for posttraumatic stress disorder (PTSD). To investigate the efficacy, safety, and tolerability of brexpiprazole and sertraline combination treatment (brexpiprazole + sertraline) compared with sertraline + placebo for PTSD. This was a parallel-design, double-blind, randomized clinical trial conducted from October 2019 to August 2023. The study had a 1-week, placebo run-in period followed by an 11-week, double-blind, randomized, active-controlled, parallel-arm period (with 21-day follow-up) and took place at 86 clinical trial sites in the US. Adult outpatients with PTSD were enrolled (volunteer sample). Oral brexpiprazole 2 to 3 mg per day (flexible dose) + sertraline 150 mg per day or sertraline 150 mg per day + placebo (1:1 ratio) for 11 weeks. The primary end point was change in Clinician-Administered PTSD Scale for DSM-5 (CAPS-5) total score (which measures the severity of 20 PTSD symptoms) from randomization (week 1) to week 10 for brexpiprazole + sertraline vs sertraline + placebo. Safety assessments included adverse events. A total of 1327 individuals were assessed for eligibility. After 878 screen failures, 416 participants (mean [SD] age, 37.4 [11.9] years; 310 female [74.5%]) were randomized. Completion rates were 137 of 214 participants (64.0%) for brexpiprazole + sertraline and 113 of 202 participants (55.9%) for sertraline + placebo. At week 10, brexpiprazole + sertraline demonstrated statistically significant greater improvement in CAPS-5 total score (mean [SD] at randomization, 38.4 [7.2]; LS mean [SE] change, -19.2 [1.2]; n = 148) than sertraline + placebo (randomization, 38.7 [7.8]; change, -13.6 [1.2]; n = 134), with LS mean difference, -5.59 (95% CI, -8.79 to -2.38; P < .001). All key secondary and other efficacy end points were also met. Treatment-emergent adverse events with incidence of 5% or greater for brexpiprazole + sertraline (and corresponding incidences for sertraline + placebo) were nausea (25 of 205 [12.2%] and 23 of 196 [11.7%]), fatigue (14 of 205 [6.8%] and 8 of 196 [4.1%]), weight increase (12 of 205 [5.9%] and 3 of 196 [1.5%]), and somnolence (11 of 205 [5.4%] and 5 of 196 [2.6%]). Discontinuation rates due to adverse events were 8 of 205 participants (3.9%) for brexpiprazole + sertraline and 20 of 196 participants (10.2%) for sertraline + placebo. Results of this randomized clinical trial show that brexpiprazole + sertraline combination treatment statistically significantly improved PTSD symptoms vs sertraline + placebo, indicating its potential as a new efficacious treatment for PTSD. Brexpiprazole + sertraline was tolerated by most participants, with a safety profile consistent with that of brexpiprazole in approved indications. ClinicalTrials.gov Identifier: NCT04124614.
Reoperative Interval and Perioperative Mortality Risk in Cardiac Surgery
Authors: Richard Ramsingh, Mariana Kawalet, Joshua E. Insler, Jules J. Bakhos, Abhishek Sharma, Penny L. Houghtaling, Marijan Koprivanac, Patrick R. Vargo, Michael Z. Tong, Haytham Elgharably, Edward G. Soltesz, Nicholas G. Smedira, Eric E. Roselli, Shinya Unai, Gösta B. Pettersson, Eugene H. Blackstone, A. Marc Gillinov, Lars G. Svensson, Faisal G. Bakaeen
Journal: JAMA Surgery (2024)

This research letter discusses the association between reoperative interval and perioperative mortality risk in cardiac surgery.